Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01370460 · ClinicalTrials.gov registry record · Phase 2

Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty

A Phase 2 study of Osteoarthritis, Knee and Acute Blood Loss Anemia, sponsored by Henry Ford Health System.

Completed
Registry status
Phase 2
Development phase
101
Enrollment target
1
Study location

NCT01370460 is a Phase 2 study of Osteoarthritis, Knee and Acute Blood Loss Anemia that has completed, run by Henry Ford Health System. The registered enrollment target is 101 participants, below the 579-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01370460, a Phase 2 study of Osteoarthritis, Knee and Acute Blood Loss Anemia, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
Phase 2
Development phase
101 participants
Enrollment target
1
Study location

Study Summary

This study aims to assess postoperative blood loss and transfusion rates in total knee replacement after one-time administration of topical tranexamic acid.

Interventions

  • DRUG Placebo
  • DRUG Tranexamic Acid

Study Locations (1)

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2011-06
Est. Completion 2012-09
Phase Phase 2

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT01370460

The ClinicalTrials.gov registry entry for NCT01370460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 579-participant average among 91 other Osteoarthritis, Knee trials with a reported enrollment target (83% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01370460 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT01370460 about?

NCT01370460 is a clinical study titled "Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty". This study aims to assess postoperative blood loss and transfusion rates in total knee replacement after one-time administration of topical tranexamic acid.

What is the current status of trial NCT01370460?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2011-06. Estimated completion is 2012-09.

What conditions does trial NCT01370460 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee, Acute Blood Loss Anemia.

What interventions are being tested in trial NCT01370460?

The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (DRUG).

Who is sponsoring clinical trial NCT01370460?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01370460 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis, Knee

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.